PMID: 42009015

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.

Yamauchi Toshimasa, Becker Niels-Peter, Hagemann Christoffer Andersen, Huang Kuo-Chin, Kiyosue Arihiro, Lim Soo, Onishi Yukiko, Kosuvaripalli Ananda, Takano Tomoko, Ishigaki Yasushi

The lancet. Diabetes & endocrinology · 2026

Vol. 14, Issue 6, pp. 450-462

This entry links to third-party literature. For research use only.